ES
CYTK icon

Equitec Specialists’s Cytokinetics CYTK Stock Holding History

Equitec Specialists’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,375
Closed -$16K – 147
2020
Q1 		$16K Buy
+1,375
New +$17.5K ﹤0.01% 96

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Equitec Specialists's CYTK Position: Q2 2020 in Review

Equitec Specialists sold out of Cytokinetics (CYTK) in Q2 2020, closing a stake of 1,375 shares — an estimated $16K sold.

Equitec Specialists first reported a position in CYTK in Q1 2020 and held it in 1 quarter. The position peaked at $16K in Q1 2020. 158 funds tracked by Wall St. Rank hold CYTK as of Q2 2020.

  • Equitec Specialists reported no remaining Cytokinetics position as of Q2 2020 after selling out during the quarter.
  • Equitec Specialists sold 1,375 Cytokinetics shares in Q2 2020, an estimated $16K.
  • Equitec Specialists first reported a position in Cytokinetics in Q1 2020 and held it in 1 quarter.
  • Equitec Specialists's Cytokinetics position peaked at $16K in Q1 2020.
  • 158 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2020.

Based on Equitec Specialists's 13F filing for Q2 2020, filed 20 Jul 2020.